Core Viewpoint - The article highlights significant research upgrades for various companies, indicating a positive shift in investor sentiment and potential growth opportunities in their respective markets [1]. Group 1: Upgrades - Arete upgraded Uber (UBER) to Buy from Neutral with a price target of $125, increased from $82, citing that concerns over competition from autonomous vehicles are overstated [2]. - Arete upgraded Lyft (LYFT) to Neutral from Sell with a price target of $20, up from $10, noting potential partnerships with Amazon's Zoox by 2026 [2]. - Longbow upgraded Garmin (GRMN) to Buy from Neutral with a price target of $250, arguing that the recent 25% decline in shares is an overreaction to anticipated revenue challenges in the automotive sector in early 2026 [2]. - Morgan Stanley upgraded Vertex Pharmaceuticals (VRTX) to Overweight from Equal Weight with a price target of $516, up from $438, reflecting a more optimistic view on the company's kidney franchise pipeline [2]. - William Blair upgraded Driven Brands (DRVN) to Outperform from Market Perform after positive management meetings, indicating improved confidence in the company's leadership stability [2].

Kidney Program Updates at the American Society of Nephrology Kidney Week 2025 November 8, 2025 ©2025 Vertex Pharmaceuticals Incorporated ©2025 Vertex Pharmaceuticals Incorporated Presentation intended for the investment community Agenda Welcome Susie Lisa, CFA, Senior Vice President, Investor Relations, Vertex Pharmaceuticals Kidney portfolio Reshma Kewalramani, M.D., President and Chief Executive Officer, Vertex Pharmaceuticals RUBY-3 late breaking data recap James A. Tumlin, M.D., Professor of Medicine in ...